Autolus Therapeutics plc American Depositary Share (AUTL)

About AUTL

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

752

Website

www.autolus.com

Fundamentals

1-day range

$2.31$2.4

Market cap

$484.40M

P/E (trailing)

—

P/E (forward)

-3.77

EPS (trailing)

$-1.06

Dividend yield

—

Beta

—

Avg. volume

1.93M

Forecasts

8 analyst ratings

Autolus Therapeutics plc American Depositary Share Competitors

Chosen by industry and closest market cap.

• AUTL

  Autolus Therapeutics plc American Depositary Share

  $2.34

  ▼ 1.06%
  Market cap $484.40MP/E —
  $1.18$2.58
• VALN

  Valneva SE American Depositary Shares

  $6.43

  ▼ 2.13%
  Market cap $491.51MP/E —
  $2.03$5.34
• PROK

  ProKidney Corp. Class A Ordinary Shares

  $1.84

  ▲ 1.10%
  Market cap $471.21MP/E —
  $1.3$3.48
• PRME

  Prime Medicine Inc. Common Stock

  $3.62

  ▼ 0.69%
  Market cap $507.54MP/E —
  $2.67$6.94
• KYTX

  Kyverna Therapeutics Inc. Common Stock

  $8.36

  ▼ 3.24%
  Market cap $456.57MP/E —
  $3.55$13.67
• ZURA

  Zura Bio Limited Class A Ordinary Shares

  $5.73

  ▼ 2.05%
  Market cap $524.39MP/E —
  $1.88$7.44
• TECX

  Tectonic Therapeutic Inc. Common Stock

  $35.69

  ▼ 2.75%
  Market cap $526.83MP/E —
  $14.39$39.53

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

133.84M

Total value held

$183.50M

Institutional holders

83